Decreased expression of Bax is correlated with poor prognosis in oral and oropharyngeal carcinoma

Cancer Letters

Volumn 140, Issue 1-2, 1999, Pages 81-91

  Ito, Toshihisa ^a   Fujieda, Shigeharu ^a   Tsuzuki, Hideaki ^a   Sunaga, Hiroshi ^a   Fan, Guo Kang ^a   Sugimoto, Chizuru ^a   Fukuda, Masaru ^a   Saito, Hitoshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

Apoptosis; Bax; Bcl 2; Oral and oropharyngeal cancer; p53

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER STAGING; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; SURVIVAL; TUMOR GROWTH;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MOUTH NEOPLASMS; OROPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033048446     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00055-5     Document Type: Article

References (42)

1. Raff M.C. Social controls on cell survival and cell death. Nature. 356:1992;397-400.
2. Kerr J.F., Wyllie A.H., Currie A.R. A basic biological phenomenon with wide-ranging implication in tissue kinetics. Br. J. Cancer. 26:1972;239-257.
3. Miyashita T., Krajewski S., Krajewska M., Wang H.G., Lin H.K., Liebermann D.A., Hoffman B. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
4. Oltvai Z.N., Milliman C.L., Korsmeyer S.J. Bcl-2 heterodimerizes in vivo with a conserved homology, Bax, that accelerates programmed cell death. Cell. 74:1993;609-619.
5. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B., Craig R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
6. Fritsche M., Haessler C., Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene. 8:1993;307-318.
7. Maltzman W., Czyzk L. UV irradiation stimulates levels of p53 cellular tumor antigen in non-transformed mouse cells. Mol. Cell Biol. 4:1984;1689-1694.
8. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A., Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
9. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:1993;957-967.
10. Kuerbitz S.J., Plunkett B.S., Walsh W.V., Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA. 89:1992;7491-7495.
11. Yin Y., Tainsky M.A., Bischoff F.Z., Strong L.C., Wahl G.W. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell. 70:1992;937-948.
12. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature. 352:1991;345-347.
13. Farmer G., Bargonetti J., Zhu H., Friedman P., Prywes R., Prives C. Wild-type p53 activates transcription in vitro. Nature. 358:1992;83-86.
14. Sachs L., Lotem J. Control of programmed cell death in normal and leukemia cells: new implications for therapy. Blood. 82:1993;15-21.
15. Bartek J., Bartkova B., Vojtesek B., Staskova Z., Lulas J., Rejthar A., Kovarik J., Midgley C.A., Gannon J.V., Lano D.P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene. 6:1991;1699-1703.
16. Cattoretti G., Rilke F., Andreola S., Amato L.D., Delia D. p53 expression in breast cancer. Int. J. Cancer. 41:1988;178-183.
17. Hall P.A., Ray A., Lemoine N.R., Midgley C.A., Krauz T., Lane D.P. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet. 338:1991;513.
18. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of human bax gene. Cell. 80:1995;293-299.
19. Reed J.C. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
20. Eliopoulos A.G., Kerr D.J., Herod J., Hodgkins L., Krajewski S., Reed J.C., Young L.S. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995;111217-111228.
21. Chresta C.M., Masters J.R.W., Hickman J.A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with p53 and high Bax: Bcl-2 ratio. Cancer Res. 56:1996;1834-1841.
22. Krajewski S., Blomqvist C., Franssila K., Krajewska M., Wasenius V.-M., Niskanen E., Nordling S., Reed J.C. Reduced expression of proapoptotic gene Bax is associated with poor response rate to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 55:1995;4471-4478.
23. Koshida Y., Saegusa M., Okayasu I. Apoptosis, cell proliferation and expression of Bcl-2 and Bax in gastric carcinomas: immunohistochemical and clinicopathological study. Br. J. Cancer. 75:1997;367-373.
24. Krajewski S., Thor A.D., Edgerton S.W., Moore D.H. II, Krajewska M., Reed J.C. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers. Clin. Cancer Res. 3:1997;199-208.
25. Yin C., Knudoson C.M., Korsmeyer S.J., Dyke T.V. Bax suppresses tumorigenesis and stimulates apoptosis in vivo. Nature. 385:1997;637-640.
26. Bargou R.C., Wagener C., Bommert K., Mapara M.Y., Daniel P.T., Arnold W., Dietel M., Guski H., Feller A., Royer H.D., Dorken B. Overexpression of the death-promoting gene bax-α which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest. 11:1996;2651-2659.
27. Sakakura C., Sweeney E.A., Shirahama T., Igarashi Y., Hakomori S., Nakatani H., Tujimoto H., Imanishi T., Ohgaki M., Ohyama T., Yamazaki J., Hagiwara A., Yamaguchi T., Sawai K., Takahashi T. Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. Int. J. Cancer. 67:1996;101-105.
28. Ohsaki Y., Toyoshima E., Fujiuchi S., Matsui H., Hirata S., Miyokawa N., Kubo Y., Kikuchi K. bcl-2 and p53 protein expression in non-small cell lung cancer: correlation with survival time. Clin. Cancer Res. 2:1996;915-920.
29. Gallo O., Boddi V., Calzolari A., Simonetti L., Trovati M., Bianchi S. Bcl-2 protein expression correlates with recurrence and survival in early stage head and neck cancer treated by radiotherapy. Clin. Cancer Res. 2:1996;261-267.
30. Gasparini O., Weidner N., Maluta S., Pozza F., Boracchi P., Mezzetti M., Testolin A., Bevilacqua P. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int. J. Cancer. 55:1993;739-744.
31. Spafford M.F., Koeppe J., Pan Z., Archer P.G., Meyers A.D., Franklin W.A. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch.Otolaryngol. Head Neck Surg. 122:1996;627-632.
32. Volm M., Efferth T., Matten J. Oncoprotein (c-myc, c-erbB1, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res. 12:1992;11-20.
33. Field J.K., Pavelic Z.P., Spandidos D.A., Stambrook P.J., Jones A.S., Gluckman J.L. The role of the p53 tumor suppressor gene in squamous cell carcinoma of head and neck. Arch. Otolaryngol. Head Neck Surg. 119:1993;1118-1122.
34. Wilson G.D., Rickinan P.I., Dische S., Saunder M.I., Robinson B., Daley F.M., Ross D.R. P53 status of head and neck cancer: relation to biological characteristics and outcome of radiotherapy. Br. J. Cancer. 71:1995;1248-1252.
35. Sauter E.R., Ridge J.A., Gordon J., Eisenberg B.L. P53 overexpression correlates with increased survival in patients with squamous carcinoma of the tongue base. Am. J. Surg. 164:1992;651-653.
36. Gallo O., Chiarelli I., Bianchi S., Calzolari A., Simonetti L., Porfirio B. Loss of p53 gene mutation after irradiation is associated with increased aggressiveness in recurring head and neck cancer. Clin. Cancer Res. 2:1996;1577-1582.
37. WAF1 and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with long-term follow-up. Clin. Cancer Res. 2:1996;1591-1599.
38. Yang B., Stambrook P.J., Markowitz S.D. Wild-type p53 demonstrates functional dominance in a human colon carcinoma cell line in which it induces reversible growth arrest. Clin. Cancer Res. 2:1996;1639-1647.
39. Smith M.L., Kontny H.U., Zhan Q., Sreenath A., O'Connor P.M., Fornace A.J. Jr. Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation of cisplatin. Oncogene. 13:1996;2255-2263.
40. Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K., Kitada S., Reed J.C. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol. 148:1996;1567-1576.
41. Evan G.I., Wyllie A.H., Gilibert S.C., Littlewood T.D., Land H., Brooks M., Waters C.M., Penn L.Z., Hancock D.C. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 69:1992;119-128.
42. Sakamuro D., Eviner V., Elliott K.J., Showe L., White E., Prendergast G. c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene. 11:1995;2411-2418.